AstraZeneca's star respiratory drug runs into another wall with COPD, but it's not giving up — yet
AstraZeneca’s attempt to push its respiratory biologic Fasenra (benralizumab) into the chronic obstructive pulmonary disease field has been foiled by a Phase III flop.
In the 56-week multi-center trial, Fasenra failed to spur a statistically significant reduction of exacerbations in patients with moderate to very severe COPD, the primary endpoint, compared to placebo.
Currently approved as an add-on treatment for severe eosinophilic asthma in the US, EU, Japan and several other countries, Fasenra was billed as a blockbuster in the making, with CEO Pascal Soriot estimating peak sales potential at $2 billion (Jefferies analysts gave it a more modest $1.5 billion).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.